The role of gender and biological sex in irritable bowel syndrome

Current Gastroenterology Reports

Volumn 7, Issue 4, 2005, Pages 257-263

  Frissora, Christine L ^a   Koch, Kenneth L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTON PUMP INHIBITOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; TEGASEROD;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACNE; ANXIETY; CENTRAL NERVOUS SYSTEM; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL MOTILITY; GENDER; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; STRESS; SYMPTOMATOLOGY;

EID: 24044505976     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0017-x     Document Type: Review

References (70)

1. Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45:II43-II47.
2. Frank L, Kleinman L, Rentz A, et al.: Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002, 24:675-689.
3. Koloski NA, Talley NJ, Boyce PM: The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000, 95:67-71.
4. Gralnek IM, Hays RD, Kilbourne A, et al.: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000, 119:654-660.
5. Schuster MM: Defining and diagnosing irritable bowel syndrome. Am J Manag Care 2001, 7(Suppl):S246-S251.
6. Silk DB: Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol 2001, 13:1327-1332.
7. Dancey CP, Backhouse S: Towards a better understanding of patients with irritable bowel syndrome. J Adv Nurs 1993, 18:1443-1450.
8. International Foundation for Functional Gastrointestinal Disorders: IBS in the Real World Survey: Summary Findings. Milwaukee, WI: International Foundation for Functional Gastrointestinal Disorders; 2002.
9. Martin R, Barron JJ, Zacker C: Irritable bowel syndrome: toward a cost-effective management approach. Am J Manag Care 2001, 78:S268-S275.
10. American Gastroenterological Association: The Burden of Gastrointestinal Diseases. Bethesda, MD: American Gastroenterological Association; 2001.
11. Brandt LJ, Bjorkman D, Fennerry MB, et al.: Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(Suppl):S7-S26.
12. Drossman DA, Whitehead WE, Camilleri M: Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997, 112:2120-2137.
13. Drossman DA, Li Z, Andruzzi E, et al.: U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993, 38:1569-1580.
14. Borum ML: Gastrointestinal diseases in women. Med Clin North Am 1998, 82:21-50.
15. Toner BB, Akman D: Gender role and irritable bowel syndrome: literature review and hypothesis. Am J Gastroenterol 2000, 95:11-16.
16. Hochstrasser B, Angst J: The Zurich Study: XXII. Epidemiology of gastrointestinal complaints and comorbidity with anxiety and depression. Eur Arch Psychiatry Clin Neurosci 1996, 246:261-272.
17. Knight LC, Parkman HP, Brown KL, et al.: Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. Am J Gastroenterol 1997, 92:968-975.
18. Teff KL, Alavi A, Chen J, et al.: Muscarinic blockade inhibits gastric emptying of mixed-nutrient meal: effects of weight and gender. Am J Physiol 1999, 276:R707-R714.
19. Berkley KJ: Sex differences in pain. Behav Brain Sci 1997, 20:371-380.
20. Unruh AM: Gender variations in clinical pain experience. Pain 1996, 65:123-167.
21. Arendt-Nielsen L, Bajaj P, Drewes AM: Visceral pain: gender differences in response to experimental and clinical pain. Eur J Pain 2004, 8:465-472.
22. Lee OY, Mayer EA, Schmulson M, et al.: Gender-related differences in IBS symptoms. Am J Gastroenterol 2001, 96:2184-2193.
23. Munakata J, Naliboff B, Harraf F, et al.: Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997, 112:55-63.
24. Ragnarsson G, Bodemar G: Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand J Gastroenterol 1999, 34:993-1000.
25. Chang L, Lee OY, Naliboff B, et al.: Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol 2001, 96:3341-3347.
26. Naliboff BD, Berman SM, Chang L, et al.: Gender related differences in central responses to rectal and sigmoid distension in irritable bowel syndrome. Gastroenterology 2003, 122:A-310.
27. Kern MK, Jaradeh S, Arndorfer RC, et al.: Gender differences in cortical representation of rectal distension in healthy humans. Am J Physiol Gastrointest Liver Physiol 2001, 2816:G1512-G1523.
28. Berman S, Munakata J, Naliboff BD, et al.: Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain 2000, 4:157-172.
29. Naliboff BD, Berman S, Chang L, et al.: Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003, 124:1738-1747.
30. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ III: Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991, 101:927-934.
31. Nyhlin H, Ford MJ, Eastwood J, et al.: Non-alimentary aspects of the irritable bowel syndrome. J Psychosom Res 1993, 37:155-162.
32. Talley NJ, Boyce P, Jones M: Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998, 42:690-695.
33. Corney RH, Stanton R: Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 1990, 34:483-491.
34. Simren M, Abrahamsson H, Svedlund J, Bjornsson ES: Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand J Gastroenterol 2001, 36:545-552.
35. Lau EM, Chan FK, Ziea ET, et al.: Epidemiology of irritable bowel syndrome in Chinese. Dig Dis Sci 2002, 47:2621-2624.
36. Manning AP, Thompson WG, Heaton KW, Morris AF: Towards positive diagnosis of the irritable bowel. BMJ 1978, 2:653-654.
37. Smith RC, Greenbaum DS, Vancouver JB, et al.: Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology 1991, 100:591-595.
38. Borum ML: Physician perception of IBS management in women and men. Dig Dis Sci 2002, 47:236-237.
39. Gershon MD: Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999, 13:15-30.
40. Crowell MD: The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care 2001, 78 (Suppl):S252-S260.
41. Gershon MD: Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004, 20:3-14.
42. Cremonini F, Delgado-Aros S, Camilleri M: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003, 15:79-86.
43. Lotronex (alosetron hydrochloride) tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2002.
44. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15:1655-1666.
45. Novick J, Miner P, Krause R, et al.: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002, 16:1877-1888.
46. Zelnorm (tegaserod maleate) tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004.
47. Camilleri M, Mayer EA, Drossman DA, et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149-1159.
48. Koch KM, Palmer JL, Noordin N, et al.: Sex and age differences in the pharmacokinetics of alosetron. Br J Clin Pharmacol 2002, 53:238-242.
49. Chang L, Ameen VZ, Dukes GE, et al.: A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005, 100:115-123.
50. Hoseini-Asl MK, Amra B: Prevalence of irritable bowel syndrome in Shahrekord, Iran. Indian J Gastroenterol 2003, 22:215-216.
51. Kwan D: Managing Parkinson's disease: levodopa and carbidopa. J Geriatr Care 2002, 1:243-244.
52. Gwee KA, Wee S, Wong ML, Png DJ: The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an asian urban community. Am J Gastroenterol 2004, 99:924-931.
53. Pimparkar BD: Irritable colon syndrome. J Indian Med Assoc 1970, 54:95-103.
54. Kane SV, Sable K, Hanauer SB: The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol 1998, 93:1867-1872.
55. Whitehead WE, Cheskin LJ, Heller BR, et al.: Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology 1990, 98:1485-1489.
56. Heitkemper M, Carter E, Ameen V, et al.: Women with irritable bowel syndrome: differences in patients' and physicians' perceptions. Gastroenterol Nurs 2002, 25:192-200.
57. Houghton LA, Lea R, Jackson N, Whorwell PJ: The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002, 50:471-474.
58. Wald A, Van Thiel DH, Hoechstetter L, et al.: Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 1981, 80:1497-1500.
59. Turnbull GK, Thompson DG, Day S, et al.: Relationships between symptoms, menstrual cycle and orocaecal transit in normal and constipated women. Gut 1989, 30:30-34.
60. Heitkemper MM, Shaver JF, Mitchell ES: Gastrointestinal symptoms and bowel patterns across the menstrual cycle in dysmenorrhea. Nurs Res 1988, 37:108-113.
61. Jackson NA, Houghton LA, Whorwell PJ, Currer B: Does the menstrual cycle affect anorectal physiology? Dig Dis Sci 1994, 39:2607-2611.
62. Crowell MD, Dubin NH, Robinson JC, et al.: Functional bowel disorders in women with dysmenorrhea. Am J Gastroenterol 1994, 89:1973-1977.
63. Chang L, Heitkemper MM: Gender differences and irritable bowel syndrome. Gastroenterology 2002, 123:1686-1701.
64. Houghton LA, Jackson NA, Whorwell PJ, Morris J: Do male sex hormones protect from irritable bowel syndrome? Am J Gastroenterol 2000, 95:2296-2300.
65. Lewis MJV, Houghton LA, Whorwell PJ: Abdominal distension in females with irritable bowel syndrome (IBS): the effect of the menopause and hormone replacement therapy. Gut 2001, 48:A43.
66. Miller V, Whitaker K, Morris JA, Whorwell PJ: Gender and irritable bowel syndrome: the male connection. J Clin Gastroenterol 2004, 38:558-560.
67. Garakani A, Win T, Virk S, et al.: Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 2003, 10:61-67.
68. North CS, Downs D, Clouse RE, et al.: The presentation of irritable bowel syndrome in the context of somatization disorder. Clin Gastroenterol Hepatol 2004, 2:787-795.
69. Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002, 122:1140-1156.
70. Blanchard EB, Keefer L, Galovski TE, et al.: Gender differences in psychological distress among patients with irritable bowel syndrome. J Psychosom Res 2001, 50:271-275.